Publications by authors named "F Cantini"
Article Synopsis
- The study evaluated the effectiveness and retention rate of secukinumab (SCK) in patients with axial spondyloarthritis (ax-SpA) using data from five Italian centers.
- A total of 71 patients were analyzed, showing significant improvements in disease activity over 24 months, with BASDAI scores decreasing from 6.2 to 3.5 and ASDAS-CRP from 2.9 to 1.7.
- Though 72% of patients remained on SCK after two years, those with fibromyalgia had a higher dropout rate, indicating that coexisting conditions may affect treatment adherence.
Calcium- and Integrin-Binding protein 2 (CIB2) is a widely expressed protein with an uncertain biological role. Two of its four EF-hand motifs bind Mg(II) and/or Ca(II), thus triggering conformational changes. Although previous studies suggested that CIB2 preferentially binds Mg(II) over Ca(II) under physiological conditions, an atomic level characterization of CIB2 in the presence of both cations was lacking.
View Article and Find Full Text PDFThis study presents a significant development in the Energy-Resolved Neutron Imaging System RADEN, in the Japan Proton Accelerator Research Complex, Japan. Through a systematic study, the collimation power of the facility was reevaluated. What was initially considered to be values of 230, 420, and 760 have been proven to be much higher.
View Article and Find Full Text PDFThe conservation of the main protease in viral genomes, combined with the absence of a homologous protease in humans, makes this enzyme family an ideal target for developing broad-spectrum antiviral drugs with minimized host toxicity. GC-376, a peptidomimetic 3CL protease inhibitor, has shown significant efficacy against coronaviruses. Recently, a GC-376-based PROTAC was developed to target and induce the proteasome-mediated degradation of the dimeric SARS-CoV-2 3CL protein.
View Article and Find Full Text PDFBackground: According to recent data, the age of patients could represent an important risk factor for MACE (major cardiovascular events), cancer, and VTE (venous thromboembolism) during treatment with JAK inhibitors in rheumatoid arthritis. We decided to analyze the population involved in the ReLiFiRa study by identifying two groups of patients: 65 years or more and less than 65 years of age, evaluating the efficacy and tolerability of 200 mg of Filgotinib daily.
Methods: Of the 120 ReLiFiRa patients, 54 were younger than 65 years old and 66 patients were 65 years old or older.